192 related articles for article (PubMed ID: 38575456)
1. Advances in Systemic Therapy in Pancreatic Cancer.
Yu KH
Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
4. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
[TBL] [Abstract][Full Text] [Related]
7. Emerging Treatment Strategies in Pancreatic Cancer.
Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
[TBL] [Abstract][Full Text] [Related]
8. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
Golan T; Javle M
J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866
[TBL] [Abstract][Full Text] [Related]
9. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
10. Next-generation therapies for pancreatic cancer.
Buckley CW; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract][Full Text] [Related]
12. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
13. Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.
Maginn EN; de Sousa CH; Wasan HS; Stronach EA
Biochim Biophys Acta; 2014 Aug; 1846(1):45-54. PubMed ID: 24727386
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.
Ayasun R; Saridogan T; Gaber O; Sahin IH
Clin Colorectal Cancer; 2023 Mar; 22(1):2-11. PubMed ID: 36418197
[TBL] [Abstract][Full Text] [Related]
15. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
16. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
17. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
18. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
